Researchers at Clemson University and Prisma Health have received funding to collaborate on the development of new medical treatment and diagnostic technologies.
Three Clemson-Prisma Health collaborations received investments from the recently created Innovation Maturation Fund, a joint effort between the Health Sciences Center (HSC) at Prisma Health and the Clemson University Division of Research. The program provides health care-focused grants designed to advance the development and commercialization of innovative medical initiatives and translational science, to improve the health care industry and to promote economic growth in the region.
The projects supported by this fund include a system to monitor triggers affecting respiratory health, injectable tissue regeneration technology and a monitoring device for patients with chronic kidney disease.
This year’s Innovation Maturation Fund awards range from $20,000 to $35,000 and were granted to:
- Brian Booth, assistant professor in the department of bioengineering, and Jeffery Edenfield, medical director at the Prisma Health Institute for Translational Oncology Research (ITOR), to further develop a collagen-type medical implant that could greatly aid in breast tissue regeneration post-lumpectomy and prevent the recurrence of tumors.
- Goutam Koley, professor in the department of electrical and computer engineering, and Steve Snodgrass, pediatric pulmonologist, to develop a mobile sensor system that monitors environmental triggers for respiratory health issues that are especially prevalent in patients with respiratory illnesses. The monitoring system will utilize a battery powered miniaturized sensor system with cellular data connectivity that can be carried in person to continuously monitor specific environmental parameters for an individual.
- Robert Latour, McQueen-Quattlebaum Professor in the department of bioengineering, and Sudha Garimella, clinical assistant professor in the School of Health Research and medical director of the Division of Pediatric Nephrology and Hypertension at Prisma Health–Upstate, t0 continue to develop ammonia breath-test sensors that can be used by patients with chronic kidney disease (CKD) to measure the ammonia concentration in their exhaled breath. This technology would enable patients with CKD to monitor their physiologic status within the comfort of their own homes.
Managed by the Clemson University Research Foundation, the goal of the fund is to increase applied research collaborations between Clemson faculty, graduate students and Prisma Health clinicians and to promote ideation and design of medical technology innovations that are attractive for commercialization.
“The Innovation Maturation Fund is a special funding program that was developed in conjunction with the Clemson Division of Research and Prisma Health to target unmet needs in the health care industry,” said Chris Gesswein, executive director of the Clemson University Research Foundation. “I am excited to be able to participate in granting the first round of funds to deserving researchers through this new program. An important step towards fostering and supporting innovation in health sciences, with this program we have the unique opportunity to accelerate the commercialization of medical technologies in an effort to create a more self-sustaining model for promoting growth in health care.”
“Prisma Health is excited to partner with Clemson University to engage companies and researchers in developing the next innovative breakthroughs in healthcare,” said Cody Reynolds, technology transfer manager in the Office of Innovation at Prisma Health-Upstate. “The Innovation Maturation Fund provides early-stage technical solutions to clinical opportunities and access to clinical learning environments that will equip researchers with the tools necessary to successfully obtain public and private funding.”